All In Biotech

NDA 202292 · Napo Pharms INC

Mytesi

Crofelemer · Oral · Antidiarrheal

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Dec 31, 2012

Approved uses

1

Original approval plus efficacy supplements

Registered trials

16

5 Phase 3, 1 recruiting

FAERS reports

239

84 serious, 29 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 31, 2026.

MYTESI is indicated for symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. MYTESI is an anti-diarrheal indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. ( 1 )

Mechanism: Crofelemer is an inhibitor of both the cyclic adenosine monophosphate (cAMP)-stimulated cystic fibrosis transmembrane conductance regulator (CFTR) chloride ion (Cl¯) channel, and the calcium-activated Cl¯ channels (CaCC) at the luminal membrane of enterocytes. The CFTR Cl¯ channel and CaCC regulate Cl¯ and fluid secretion by intestinal epithelial cells. Crofelemer acts by blocking Cl¯ secretion and accompanying high volume water loss in diarrhea, normalizing the flow of Cl¯ and water in the gastrointestinal tract.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • MYTESI · CROFELEMER 125MG · TABLET, DELAYED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Crofelemer" as an intervention, any sponsor and status, largest first.

All 16 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use61
  • drug ineffective51
  • product dose omission issue29
  • diarrhoea26
  • death23
  • pain17
  • anxiety14
  • emotional distress14
  • anhedonia12
  • fatigue11
  • chronic kidney disease10
  • dizziness10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20141
20161
20173
20185
20195
20207
202114
202239
202343
202446
202540
202634

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mytesi (Crofelemer)

2024 spending

$8.0M

Beneficiaries

376

2,591 claims

Per beneficiary

$21,348

$41.50 per unit

View as table
YearSpending
2020$8,432,051
2021$9,047,448
2022$7,379,846
2023$7,449,992
2024$8,026,902

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7 on PubMed

Sponsor: Napo Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.